Logo image of TRAW

TRAWS PHARMA INC (TRAW) Stock Overview

USA - NASDAQ:TRAW - US68232V8845 - Common Stock

2.86 USD
+0.19 (+7.12%)
Last: 10/17/2025, 8:00:01 PM
2.8 USD
-0.06 (-2.1%)
After Hours: 10/17/2025, 8:00:01 PM

TRAW Key Statistics, Chart & Performance

Key Statistics
Market Cap20.39M
Revenue(TTM)2.90M
Net Income(TTM)87.91M
Shares7.13M
Float5.48M
52 Week High19.44
52 Week Low0.97
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)19.77
PE0.14
Fwd PEN/A
Earnings (Next)11-12 2025-11-12
IPO2013-07-25
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


TRAW short term performance overview.The bars show the price performance of TRAW in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

TRAW long term performance overview.The bars show the price performance of TRAW in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of TRAW is 2.86 USD. In the past month the price increased by 40.89%. In the past year, price decreased by -41.21%.

TRAWS PHARMA INC / TRAW Daily stock chart

TRAW Latest News, Press Relases and Analysis

TRAW Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 49.71 759.85B
JNJ JOHNSON & JOHNSON 18.61 465.34B
AZN ASTRAZENECA PLC-SPONS ADR 19.07 262.58B
NVS NOVARTIS AG-SPONSORED ADR 14.85 254.43B
NVO NOVO-NORDISK A/S-SPONS ADR 13.94 241.59B
MRK MERCK & CO. INC. 11.01 211.79B
PFE PFIZER INC 7.23 139.35B
SNY SANOFI-ADR 11.4 123.36B
BMY BRISTOL-MYERS SQUIBB CO 6.48 88.81B
GSK GSK PLC-SPON ADR 9.74 88.32B
ZTS ZOETIS INC 23.16 63.84B
TAK TAKEDA PHARMACEUTIC-SP ADR 48.41 44.34B

About TRAW

Company Profile

TRAW logo image Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2013-07-25. The company integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.

Company Info

TRAWS PHARMA INC

12 Penns Trail

Newtown PENNSYLVANIA US

Employees: 7

TRAW Company Website

TRAW Investor Relations

Phone: 12677593680

TRAWS PHARMA INC / TRAW FAQ

What is the stock price of TRAWS PHARMA INC today?

The current stock price of TRAW is 2.86 USD. The price increased by 7.12% in the last trading session.


What is the ticker symbol for TRAWS PHARMA INC stock?

The exchange symbol of TRAWS PHARMA INC is TRAW and it is listed on the Nasdaq exchange.


On which exchange is TRAW stock listed?

TRAW stock is listed on the Nasdaq exchange.


What is TRAWS PHARMA INC worth?

TRAWS PHARMA INC (TRAW) has a market capitalization of 20.39M USD. This makes TRAW a Nano Cap stock.


How many employees does TRAWS PHARMA INC have?

TRAWS PHARMA INC (TRAW) currently has 7 employees.


What are the support and resistance levels for TRAWS PHARMA INC (TRAW) stock?

TRAWS PHARMA INC (TRAW) has a support level at 2.66 and a resistance level at 2.95. Check the full technical report for a detailed analysis of TRAW support and resistance levels.


Should I buy TRAWS PHARMA INC (TRAW) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TRAWS PHARMA INC (TRAW) stock pay dividends?

TRAW does not pay a dividend.


When does TRAWS PHARMA INC (TRAW) report earnings?

TRAWS PHARMA INC (TRAW) will report earnings on 2025-11-12.


What is the Price/Earnings (PE) ratio of TRAWS PHARMA INC (TRAW)?

The PE ratio for TRAWS PHARMA INC (TRAW) is 0.14. This is based on the reported non-GAAP earnings per share of 19.77 and the current share price of 2.86 USD. Check the full fundamental report for a full analysis of the valuation metrics for TRAW.


What is the Short Interest ratio of TRAWS PHARMA INC (TRAW) stock?

The outstanding short interest for TRAWS PHARMA INC (TRAW) is 2.21% of its float. Check the ownership tab for more information on the TRAW short interest.


TRAW Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to TRAW. When comparing the yearly performance of all stocks, TRAW is one of the better performing stocks in the market, outperforming 81.74% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TRAW Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to TRAW. While TRAW seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TRAW Financial Highlights

Over the last trailing twelve months TRAW reported a non-GAAP Earnings per Share(EPS) of 19.77. The EPS increased by 114.9% compared to the year before.


Industry RankSector Rank
PM (TTM) 3028.25%
ROA 562.73%
ROE 1064.03%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%99.91%
Sales Q2Q%4694.74%
EPS 1Y (TTM)114.9%
Revenue 1Y (TTM)1184.51%

TRAW Forecast & Estimates


Analysts
Analysts82.86
Price TargetN/A
EPS Next Y76.99%
Revenue Next Year0%

TRAW Ownership

Ownership
Inst Owners9.31%
Ins Owners6.11%
Short Float %2.21%
Short Ratio1.09